Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Treatment characteristics

From: Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol

   Total group (n = 94) Study group (n = 18) Control group (n = 18) p-values*
   n % value (range) n % value (range) n % value (range)  
Surgical treatment Total 88 93.6   17 94.4   15 83.3   (0.279)
  Local resection 78 83.0   14 77.7   14 77.7   (0.397)
  Neck dissection 10 10.6   3 16.7   1 5.6   (0.790)
Brachytherapy Total dose (Gy)    25.9 (10–35)    27.0 (15–35)    27.1 (20–30) (0.696)
  Single dose (Gy)    2.5 (2.5-4.5)    2.5 (2.5-3.0)    2.5 (2.5-2.5) (0.791)
  Fractions    10.2 (4–14)    10.6 (6–14)    10.8 (8–12) (0.938)
  Radiation days    6.3 (1–11)    7.1 (4–9)    6.6 (3–9) (0.202)
  V100 (ml)    50.0 (3.6-149.5)    61.9 (22.3-149.5)    46.4 (4.0-111.1) (0.291)
  V150 (ml)    19.1 (1.6-65.3)    23.1 (7.1-55.2)    17.0 (2.0-37.3) (0.347)
  DNR    0.37 (0.32-0.56)    0.35 (0.28-0.46)    0.40 (0.29-0.56) (0.168)
Adjuvant treatment EBRT 24 25.5   4 22.2   3 16.7   (0.557)
  Radiation dose (Gy)    48.7 (30–60)    50.1 (50.0-50.4)    35.8 (30–45) (0.887)
  Chemotherapy (total) 15 16.0   18 100   2 11.1   (0.000)
  Chemotherapy (only platinum derivatives) 5 5.3   2 11.1   - -   
  1. Gives an overview of the performed treatment modalities. The ‘Cetuximab-Taxane Recurrency Scheme’ combines salvage surgery (SS), Brachytherapy (BT) and adjuvant chemoprotocol in regard to previous external radiation (EBRT), previous chemotherapy (CTx). To exhaust chances an external boost was added whenever reasonable. Differences between the study group and the control group were analyzed by *chi-square test and Mann–Whitney U test